Pharmaceutical Packaging Linked Review Takes Effect: Borosilicate Glass Standards Drive Electric Melting Upgrades

For a long time, domestic injection packaging was dominated by soda-lime glass and ordinary borosilicate glass, and the problems of vial delamination and visible particles were never fully resolved. In February 2016, the linked review and approval system for pharmaceutical packaging materials and drugs was formally implemented, under which packaging materials are reviewed together with the drug, and the substitution of medium borosilicate glass was put on a faster track. That year pharmaceutical glass producers had already begun product switching and furnace upgrades, and borosilicate glass melting processes drew attention accordingly. For glassmakers that had long produced only low-grade borosilicate, switching to medium borosilicate meant more than a formula change: furnaces, refining and forming all had to be rebuilt together.

Borosilicate 4.0 and 3.3: the difference goes beyond the numbers

Borosilicate glass is classified by linear expansion coefficient: borosilicate 4.0 glass has a higher boron oxide content, good chemical stability and thermal shock resistance, and withstands repeated sterilization; borosilicate 3.3 glass performs better in alkali resistance and suits high-end biologicals and freeze-dried products. Melting temperatures for both are higher than for ordinary glass, the melt is viscous and hard to refine, and furnaces generally need electric boosting or even all-electric melting to ensure melting and homogenization quality, which places hard requirements on electrode materials. Medium borosilicate also has a narrow melting temperature window, a highly viscous melt and slow bubble release, asking more of the refining capability of the boosting system.

Fit of high-purity molybdenum electrodes

Pharmaceutical glass is extremely sensitive to impurities and tint. Molybdenum electrodes corrode slowly in borosilicate melts, and their corrosion products do not noticeably tint the glass, making them the mainstream electrode material for pharmaceutical glass furnaces. As packaging review tightened, user requirements on the electrodes themselves rose in step:

• Higher purity: electrode molybdenum content moving toward 99.9% and above, with impurity elements held to the upper limits of the standard;
• Dense structure: a low-oxygen, low-carbon sintered structure that reduces outgassing and accelerated corrosion at high temperature;
• Full traceability: quality certificates provided by batch to support audits within the pharmaceutical packaging system;
• Dimensional accuracy: tightly controlled tolerances on large-diameter electrodes to keep insertion depth and current distribution stable.

Upgrading across the supply chain

Following this thread of glass melting, product-level parameters center on glass electric melting furnace electrode specifications.

The linked review drove an overall upgrade in refractories, power supply equipment and electrode processing; some furnace engineering firms launched electric melting furnace designs dedicated to borosilicate glass, and electrode makers adjusted their recommended current density values for high-temperature borosilicate melts. To meet these requirements, electrode makers tightened control at incoming powder, sintering atmosphere and structure inspection, and some set up dedicated clean packaging and inspection flows for pharmaceutical glass customers to avoid secondary contamination during shipping and handover. WeiBeam.com industry observation holds that domestic substitution of pharmaceutical borosilicate glass will continue for several years, and the matching demand for high-quality electrodes in its melting stage is expected to be released gradually as capacity ramps up.